Lost password ?
<< Back to Equity Research
UNIMED
UNIMED, IN FRONT OF THE RACE IN TERMS OF PROFITBILITY
Mar 13 - Despite the stock’s recovery in the beginning of this year, Unimed (Reduce, Tunisia) (23.6% YTD performance since January 2018) continues to underperform the Tunindex. Overall, Tunisian Pharmas still ...
Executive summary
Conflict of Interest
Pages 34
Language English
Publish on March 13, 2018
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 29 PM
SIPHAT
The mess continues
Apr 29 PM
SIPHAT
Declining revenue
Apr 25 AM
UNIMED
Double-digit growth in Q1
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ